NEW YORK/ BOSTON, Aug 20- A few months ago, an innovative partnership between Valeant Pharmaceuticals and billionaire investor William Ackman to buy Botox maker Allergan Inc looked like a blueprint for success.» Read More
WASHINGTON— A Canadian drugmaker working on an experimental drug for Ebola said Wednesday that it is not ready to make the treatment available in Africa, despite assurances by international health officials that it is ethical to use untested treatments to fight the deadly outbreak.
NEW YORK, Aug 13- Biotechnology company InterMune Inc is working with financial advisers to evaluate strategic options as it braces for potential takeover interest from larger drugmakers, people familiar with the matter said.
Raghuram Selvaraju, head of healthcare equity research at Aegis Capital, says "German Merck's" second quarter was "solid and respectable" but that its biopharmaceutical business is its weak spot.
Aug 13- Rigel Pharmaceuticals Inc said it would stop testing its drug for some patients with dry eye disease after the treatment failed a mid-stage study. British drugmaker AstraZeneca Plc scrapped its licensing deal for Rigel's rheumatoid arthritis treatment in June 2013.
Aug 13- Rigel Pharmaceuticals Inc said its experimental drug failed to meet the main goal in a mid-stage study in patients with dry eye disease, sending its shares down 10.7 percent in premarket trading. British drugmaker AstraZeneca stopped developing Rigel's rheumatoid arthritis treatment in June 2013.
WASHINGTON— Pfizer Inc. is teaming up with DNA testing company 23 andMe to study the possible genetic underpinnings of inflammatory bowel disease, a hard-to-treat ailment that affects an estimated 1.4 million Americans.
Dendreon Corp. shares tumbled Tuesday morning, a day after the drug developer warned shareholders that it has debt worries, and it is considering alternatives that could wipe out their ownership.
Following bright start to the trading week, positive momentum grinds to a halt Atlantic City's Revel Casino to close in September after 2- year-old resort fails to find buyer Mild goose chase: 1 Ohio airport's creative experiment to ensure birds, planes don't collide Intercept Pharmaceuticals shares soar after drugmaker updates on possible liver treatment Investment analyst survey shows Ukraine fears weighing on German business confidence Hertz delays filing of 2 Q financial results due to ongoing review of accounting errors Tiptree Financial buying insurance services company Fortegra Financial for about $218 million Kate Spade posts smaller 2nd- quarter loss, sales rise in North America and internationally US budget deficit running nearly one-third less than last year as revenues outpace spending FDA approves Exact Sciences' DNA test to help screen for colon cancer tumors
Jim Cramer explains what to watch ahead of the open, including Intercept Pharmaceuticals.
Shares of Intercept Pharmaceuticals Inc. soared in premarket trading Tuesday, a day after the drug developer said its most advanced candidate performed better than a placebo in a mid-stage study of patients with a form of chronic liver disease.
RICHMOND, Va.— The dietary supplement maker at the center of a federal trial of former Virginia Gov. Rock Creek Pharmaceuticals Inc. said Monday it is voluntarily stopping sales of Anatabloc and another supplement called CigRx while it sorts out issues with the Food and Drug Administration.
A quarter century later, Gonsalves still travels to Washington, but with a different agenda: to defend the FDA. The efforts include new state laws designed to undercut the FDA's authority by giving patients early access to unapproved drugs and a lobbying push by industry groups to speed up the time it takes the FDA to review new treatments.
MannKind Corp. is teaming up with the French pharmaceutical giant Sanofi to help develop and sell its first product to hit the market, the inhaled insulin Afrezza. MannKind will make the supply of Afrezza, and Sanofi will be responsible for global commercial, regulatory and development activities.
A clinical trial of an experimental vaccine against the deadly Ebola virus is set to start shortly, according to GlaxoSmithKline.
LONDON, Aug 10- A clinical trial of an experimental vaccine against the deadly Ebola virus is set to start shortly, according to British drugmaker GlaxoSmithKline, which is co-developing the product with U.S. scientists.
U.S. scientists face legal obstacles and frustrations in trying to study the medical uses of marijuana, the New York Times reports.
All three U.S. laboratories established to fight major public health threats say they are standing by to scale up a treatment for Ebola.
Pfizer confronts surge of lawsuits over Lipitor. Pharmaceutical giant Pfizer is facing a mounting number of lawsuits by women who say the company knew its blockbuster anti-cholesterol drug Lipitor was linked to a small increased risk of type-2 diabetes but never properly warned the public.
Tekmira Pharmaceutical's stocks have soared since the U.S. Food and Drug Administration cleared its experimental Ebola drug for human use.
Pfizer is facing a mounting wave of lawsuits by women who allege that the company knew about possible serious side effects of its drug Lipitor.